NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are ...

Saliva-based diagnostics have emerged as a transformative approach in medical testing, offering a non-invasive and efficient ...

Cytomegalovirus (CMV) infection is one of the most common congenital infections. We present a case of an infant who presented with respiratory distress since birth with a normal antenatal history. The ...

Immunoglobulin M (IgM) is also one of the first antibodies recruited by the immune system to fight infection. IgM populations rise very quickly when the body is first confronted with an infectious ...

Introduction During the first wave of the COVID-19 outbreak in China, the surge of COVID-19 cases was rapid and drastic. Emerging evidence suggests that beyond the acute phase, patients with COVID-19 ...

The therapeutic candidate is a bi-specific T cell engager IgM antibody targeting CD20 and CD3. It is being developed based on IgM antibody technology. The drug candidate was also under the development ...

The therapeutic candidate is a bi-specific T cell engager IgM antibody targeting CD20 and CD3. It is being developed based on IgM antibody technology. The drug candidate was also under the development ...

Anti-CCP antibodies were analysed by an enzyme immunoassay (EIA). Rheumatoid factors (RFs) were analysed by latex agglutination and two isotype-specific (IgM and IgA) EIAs. Disease activity was ...

lumc.nl Objective The presence of anti-citrullinated protein antibodies (ACPA) and IgM-rheumatoid factor (IgM-RF) years before the clinical diagnosis of rheumatoid arthritis (RA) suggests they are ...

Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research.

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical development of drugs in its autoimmune franchise ...